NeoGenomics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20, 2024
NeoGenomics, Inc. (NASDAQ: NEO) will report its Q4 and full year 2023 financial results on February 20, 2024. A webcast and conference call will be held to discuss the results and recent highlights. The live webcast can be accessed on the Investor Relations section of their website. The call can also be accessed via telephone with the provided participant access code.
01/30/2024 - 07:05 AM
FT. MYERS, Fla. --(BUSINESS WIRE)--
NeoGenomics, Inc. (NASDAQ: NEO), a leading oncology testing services company, today announced that it will report its fourth quarter and full year 2023 financial results on Tuesday, February 20, 2024. Company management will host a webcast and conference call that day at 4:30 p.m. Eastern Time to discuss its financial results and recent highlights.
The live webcast may be accessed by visiting the Investor Relations section of our website at ir.neogenomics.com . The webcast will be archived and available for replay shortly after the conclusion of the call.
To access the live call via telephone, dial (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call. The participant access code provided for this call is 822624.
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services, providing one of the most comprehensive oncology-focused testing menus in the world for physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL , NeoGenomics operates CAP accredited and CLIA certified laboratories for full-service sample processing in Fort Myers, Florida ; Aliso Viejo and San Diego, California ; Research Triangle Park, North Carolina ; and Houston, Texas ; and a CAP accredited full-service, sample-processing laboratory in Cambridge, United Kingdom . NeoGenomics also has several, small, non-processing laboratory locations across the United States for providing analysis services. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, pharmaceutical firms, integrated service delivery networks, and managed care organizations throughout the United States , and pharmaceutical firms in Europe and Asia .
View source version on businesswire.com: https://www.businesswire.com/news/home/20240130563560/en/
Investor Contact
Kendra Sweeney
kendra.sweeney@neogenomics.com
Media Contact
Lisa Whitmyer
lisa.whitmyer@neogenomics.com
Source: NeoGenomics, Inc.
When will NeoGenomics report its Q4 and full year 2023 financial results?
NeoGenomics will report its Q4 and full year 2023 financial results on February 20, 2024.
How can I access the live webcast of the financial results discussion?
The live webcast can be accessed by visiting the Investor Relations section of NeoGenomics website.
How can I access the conference call to discuss the financial results?
The conference call can be accessed via telephone by dialing (888) 506-0062 (domestic) or (973) 528-0011 (international) at least five minutes prior to the call with the participant access code 822624.
Neogenomics Inc.
NASDAQ:NEO
NEO Rankings
#198 Ranked by Stock Gains
NEO Stock Data
Industry
Testing Laboratories
Sector
Professional, Scientific, and Technical Services
Tags
Health Services, Medical/Nursing Services, Professional, Scientific, and Technical Services, Testing Laboratories
Country
US
City
Fort Myers
About NEO
neogenomics laboratories is a leading cancer diagnostic reference laboratory that has provided high-quality cancer testing and partnership programs to pathologists and oncologists for over 10 years. we work every day to achieve our common purpose of saving lives by improving patient care through communication, accuracy, reliability, and efficiency. our areas of expertise include cancer cytogenetics with industry-leading turnaround times; hematologic and solid tumor fish testing with the largest menu of technical-only services available; 10-color flow cytometry; ihc supported by an extensive antibody library; and over 100 molecular oncology tests comprising the most comprehensive combination of multiparameter profiles and targeted biomarker tests in the industry. our technical-only testing programs feature on-demand or live training and are available to pathologists who wish to sign out fish, flow cytometry, and/or ihc. neogenomics’ extremely fast test development cycle means we are hig